Core Insights - Riot Platforms, Inc. (RIOT) is expected to report its fourth-quarter 2025 results on March 3, with a strong earnings surprise history, having surpassed the Zacks Consensus Estimate in three of the last four quarters, averaging a 160% earnings surprise [2] Revenue Expectations - The Zacks Consensus Estimate for RIOT's revenue in Q4 2025 is $157.4 million, reflecting a 10.1% increase from the previous year, driven by growth in Bitcoin Mining and Engineering revenues [3] - Bitcoin Mining revenues are projected at $136 million, indicating a 7.6% year-over-year growth, while Engineering revenues are expected to reach $21.3 million, representing an 85% increase from the prior year [3] Strategic Developments - The company has been actively developing its data center business for bitcoin mining, including the acquisition of 67 acres adjacent to its Corsicana site to create a 1 GW utility-load data center campus, which is anticipated to enhance technical engagement with major customers [4] - Recent growth in the engineering business, particularly through ESS Metron and E4A Solutions, is expected to create synergies and expand the data center development program, contributing positively to revenue [5] Earnings Outlook - The consensus estimate for loss per share is 22 cents, a decline from a profit of 44 cents reported in the same quarter last year, reflecting the impact of the company's transformation efforts and acquisitions [6] - The company has announced the development of two new buildings at its Corsicana campus, adding 112 megawatts of critical IT data center capacity, which is expected to enhance future capabilities [7] Earnings Prediction Model - The current model does not predict an earnings beat for RIOT, with an Earnings ESP of 0.00% and a Zacks Rank of 1 (Strong Buy), indicating that while the potential for an earnings beat exists, it is not strongly supported by the current data [8]

Core Insights - Puma Biotechnology (PBYI) reported fourth-quarter 2025 adjusted earnings of 29 cents per share, exceeding the Zacks Consensus Estimate of 24 cents, but down from 43 cents in the same quarter last year [1] - Total revenues for the fourth quarter reached $75.5 million, surpassing the Zacks Consensus Estimate of $68 million, and reflecting a 28% year-over-year increase [2] Financial Performance - Product revenues from Nerlynx totaled $59.9 million in Q4, up nearly 10% year over year, beating estimates of $54 million [4] - Royalty revenues surged 232% year over year to $15.6 million [4] - Total operating costs for the quarter were $58.4 million, an increase of 28% year over year [4] - For the full year 2025, total revenues were $228.4 million, slightly down from $230.5 million in the previous year [6] Guidance and Projections - For 2026, net product revenues are projected to be between $194 million and $198 million, with total revenues expected to range from $214 million to $221 million, which is below the Zacks Consensus Estimate of $235.7 million [7][8] - The company anticipates a net loss of approximately $8 million to $10 million for Q1 2026 [12] Pipeline Developments - Puma Biotechnology is developing alisertib, an aurora kinase A inhibitor, for hormone receptor-positive breast cancer and small-cell lung cancer [13] - The company is conducting a phase II study (ALISCA-Lung1) for alisertib as a monotherapy for extensive-stage SCLC, with interim data expected in Q2 2026 [14] - Another phase II study (ALISCA-Breast1) is underway for alisertib in combination with endocrine treatment for HER2-negative, hormone receptor-positive metastatic breast cancer, with initial data also expected in Q2 2026 [15] Market Performance - PBYI's shares have increased by 154.2% over the past year, compared to the industry's rise of 19.9% [9]

ToplineGold and silver rose Friday in the latest sign of recovery from a late January crash, reaching their highest points of February as nuclear talks between the U.S. and Iran lag with no agreement yet in sight. Gold prices have rallied since tumbling in late January. AP Photo/Matthias SchraderKey FactsGold futures edged up 1.3% just above the $5,260 mark while silver spiked 7.6% past the $94.25 mark Friday shortly after 1 p.m. EST.Spot prices followed suit, with gold up just over 1%, nearing an all-time ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Company Overview - Unisys Corporation (UIS) has experienced a significant decline in stock price, down nearly 60% since the last analysis [1] Business Operations - The company focuses on maintaining core systems for large institutions while also assisting in the management and modernization of their IT environments [1]

Core Insights - OpenAI was founded to create competition against Google in the AI sector, which Google has dominated for over 25 years [1] - OpenAI raised a record $110 billion, with significant investments from major competitors of Google [2] Investment Landscape - Amazon is investing $50 billion in OpenAI, positioning itself as a major competitor to Google in cloud computing and product search [2][3] - Nvidia has committed $30 billion to OpenAI, enhancing its competitive stance against Google in the AI chip market [6] - Microsoft remains a significant stakeholder in OpenAI, owning over 20% despite not participating in the latest funding round [8] Competitive Dynamics - Amazon's investment allows it to leverage OpenAI's technology and develop custom AI models, enhancing its cloud services [4][5] - Nvidia's partnership with OpenAI focuses on utilizing advanced computing capacity to improve AI model training and inference [7] - Microsoft continues to compete with Google across various sectors, including cloud computing and business software, with OpenAI being a strategic asset [9][10]

Biglari Capital Calls for Immediate Resignation of Jack in the Box Chairman David Goebel, Who Was Overwhelmingly Rejected by Stockholders with "Skin in the Game" [Accessibility Statement] Skip NavigationThe Company Should Not Hide Behind Its Treatment of Abstain Votes — Chairman Goebel Did Not Receive a Majority of the Votes CastJack in the Box Stockholders Cannot Afford Another Year of David GoebelISS, BlackRock, Vanguard, and State Street Inexplicably Defended Long-Tenured David Goebel and Failed to Hold ...

February 27, 20266:32 PM UTCUpdated ago By Timothy Gardner The logo of Houston-based liquefied natural gas company Cheniere seen during the LNG 2023 energy trade show in Vancouver, British Columbia, Canada, July 12, 2023. REUTERS/Chris Helgren/File Photo Purchase Licensing Rights, opens new tab WASHINGTON, Feb 27 (Reuters) - Cheniere Energy Inc (LNG.N), opens new tab disclosed this week that it got a $370 million tax break from the Trump administration for burning liquefied natural gas in its massive tanker ...

SAN FRANCISCO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is notifying investors in Ardent Health, Inc. (NYSE: ARDT) regarding the March 9, 2026, lead plaintiff deadline in a pending securities class action the company and certain of its top executives. CLICK HERE TO SUBMIT YOUR ARDT LOSSES The litigation focuses on the revelation in Nov. 2025 that Ardent alleged utilized a rigid 180-day cliff to reserve for uncollectible accounts – a process that the complaint alle ...

Key Takeaways BGS is expected to post a 9.7% year-over-year decline in Q4 earnings per share. B&G Foods sees steady base trends, with an extra fiscal week aiding sales amid soft retail volumes.BGS is using pricing actions and cost cuts to offset inflation, tariffs and elevated leverage pressures.B&G Foods, Inc. (BGS) is likely to witness a bottom-line decline when it reports fourth-quarter fiscal 2025 earnings on March 3. The consensus mark for earnings has remained unchanged in the past 30 days at 28 cents ...